Population pharmacokinetics of valganciclovir prophylaxis in paediatric and adult solid organ transplant recipients
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Population pharmacokinetics of valganciclovir prophylaxis in paediatric and adult solid organ transplant recipients
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
Volume 78, Issue 2, Pages 343-352
Publisher
Wiley
Online
2014-02-17
DOI
10.1111/bcp.12343
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Extended Valganciclovir Prophylaxis to Prevent Cytomegalovirus After Lung Transplantation
- (2013) Scott M. Palmer ANNALS OF INTERNAL MEDICINE
- The Relationship between Drug Clearance and Body Size
- (2012) Sarah C. McLeay et al. CLINICAL PHARMACOKINETICS
- Evaluation of valganciclovir pharmacokinetics in lung transplant recipients
- (2012) Tyree H. Kiser et al. JOURNAL OF HEART AND LUNG TRANSPLANTATION
- (Val-)Ganciclovir prophylaxis reduces Epstein-Barr virus primary infection in pediatric renal transplantation
- (2012) Britta Höcker et al. TRANSPLANT INTERNATIONAL
- Impact of Cytomegalovirus Disease in D+/R- Kidney Transplant Patients Receiving 6 Months Low-Dose Valganciclovir Prophylaxis
- (2011) F. L. Luan et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Ganciclovir exposure under a 450 mg daily dosage of valganciclovir for cytomegalovirus prevention in kidney transplantation: a prospective study
- (2010) Oriol Manuel et al. CLINICAL TRANSPLANTATION
- Controversy in the Allometric Application of Fixed- Versus Varying-Exponent Models: A Statistical and Mathematical Perspective
- (2010) Huadong Tang et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- GFR-estimating models in kidney transplant recipients on a steroid-free regimen
- (2010) A. Kukla et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Extended Valganciclovir Prophylaxis in D+/R− Kidney Transplant Recipients is Associated With Long-Term Reduction in Cytomegalovirus Disease: Two-Year Results of the IMPACT Study
- (2010) Atul Humar et al. TRANSPLANTATION
- Valganciclovir Dosing According to Body Surface Area and Renal Function in Pediatric Solid Organ Transplant Recipients
- (2009) W. Vaudry et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Population Pharmacokinetics of Ganciclovir in Solid-Organ Transplant Recipients Receiving Oral Valganciclovir
- (2009) N. Perrottet et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Simultaneous determination of acyclovir, ganciclovir, and (R)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine in human plasma using high-performance liquid chromatography
- (2009) Dennis R. Weller et al. BIOMEDICAL CHROMATOGRAPHY
- Population Pharmacokinetics of Ganciclovir Following Administration of Valganciclovir in Paediatric Renal Transplant Patients
- (2009) Wei Zhao et al. CLINICAL PHARMACOKINETICS
- Pharmacokinetics of oral valganciclovir solution and intravenous ganciclovir in pediatric renal and liver transplant recipients
- (2009) M.D. Pescovitz et al. Transplant Infectious Disease
- Pharmacokinetics of Low and Maintenance Dose Valganciclovir in Kidney Transplant Recipients
- (2008) C. E. Chamberlain et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Selective low-dose valganciclovir for prevention of cytomegalovirus disease following kidney transplantation
- (2008) Yafit Partouche Avidan et al. JOURNAL OF INFECTION
- Oral ganciclovir versus valganciclovir for cytomegalovirus prophylaxis in high-risk liver transplant recipients
- (2008) R.L. Brady et al. Transplant Infectious Disease
- Mechanism-Based Concepts of Size and Maturity in Pharmacokinetics
- (2007) B.J. Anderson et al. Annual Review of Pharmacology and Toxicology
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started